TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.4, a high estimate of $50.00, ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics (TGTX – Research Report), with a price ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

TD Cowen analyst Tara Bancroft maintained a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target of ...

On a per-share basis, the Morrisville, New York-based company said it had profit of 2 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The firm owned 49,900 shares of the biopharmaceutical company’s stock after buying an additional 9,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in TG Therapeutics were ...